ArticleBMC infectious diseases2014
Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Trial
- Management of severe and fulminantJournal of medical microbiology · 2025Review
- A high-throughput anaerobic method for viability assays.Microbiology spectrum · 2025Article
- Review of the Impact of Biofilm Formation on RecurrentMicroorganisms · 2023Review
- Antibacterial Effect of Lemongrass (Molecules (Basel, Switzerland) · 2022Article
- Inactivation of the riboswitch-controlled GMP synthase GuaA inRNA biology · 2021Article
- Opportunities for Nanomedicine inAntibiotics (Basel, Switzerland) · 2021Review
- Issues beyond resistance: inadequate antibiotic therapy and bacterial hypervirulence.FEMS microbes · 2020Review
- Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.Antimicrobial agents and chemotherapy · 2020Article
- Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile.Scientific reports · 2020Article
- Toxin A and B genes expression ofIranian journal of microbiology · 2020Article
- Transcriptome Analysis of theFrontiers in microbiology · 2020Article
- Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection.Nature microbiology · 2019Article
- Phenotypic Characterization of Non-toxigenicFrontiers in microbiology · 2019Article
- Single-cell electro-phenotyping for rapid assessment ofSensors and actuators. B, Chemical · 2018Article
- High Prevalence and Genetic Diversity of Large phiCD211 (phiCDIF1296T)-Like Prophages in Clostridioides difficile.Applied and environmental microbiology · 2018Article
- Effect ofFrontiers in microbiology · 2018Article
- Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018Review
- The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.Infectious diseases and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSporulation of Clostridium difficile during infection and persistence of spores within the gut could partly explain treatment failures and recurrence. However, the influence of antibiotics on sporulation is unclear. The objective of our study was to evaluate the impact of ciprofloxacin, metronidazole, piperacillin/tazobactam, tigecycline, and vancomycin on C. difficile sporulation in vitro.
methodsThe reference strains ATCC 9689, 630, VPI 10463, and seven other clinical isolates of C. difficile were used, including three epidemic NAP1/027 isolates. Minimum inhibitory concentrations (MIC) were determined and sporulation was assessed after growth in the absence or presence of ≤0.5x MIC concentrations of each antibiotic.
resultsAll strains were sensitive to the antibiotics tested, except ribotype 027 isolates that were resistant to ciprofloxacin (MIC = 128 mg/L). Metronidazole and vancomycin generally did not significantly affect spore production in C. difficile, although vancomycin slightly affected sporulation of a few isolates. Ciprofloxacin inhibited sporulation of ribotype 027 isolates mainly. Interestingly, sub-MIC concentrations of piperacillin/tazobactam reduced spore formation in several isolates. However, the most striking observation was made with tigecycline, with an important reduction of spore formation in most isolates.
conclusionsThe capacity of C. difficile to sporulate can be significantly affected by certain antibiotics. The reduced sporulation observed with tigecycline and piperacillin/tazobactam might explain why these antibiotics are generally associated with lower risk of C. difficile infections. In addition, the inhibition of sporulation might partly explain the apparent efficacy of tigecycline for treatment of patients with recurrent infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.